KFDA MFU Device Updates: New Approvals in Korean Market

I write a lot about Ultherapy because that is the platform I keep returning to as a patient — but if you spend enough time inside Gangnam clinic consultation rooms, you start to notice the device menu changing underneath you. Between January 2024 and the time of this writing in May 2026, the Korean Ministry of Food and Drug Safety (MFDS, sometimes abbreviated KFDA in older English-language sources) cleared or expanded indications for at least five MFU and adjacent ultrasound platforms that are now on Gangnam pricing sheets. This article is a reporter's read on what changed, what the regulatory pathway actually looks like, and which of those clearances meaningfully affected what a patient walks into. None of it is medical advice. I have a financial interest only in writing accurately about the device I personally use.

How KFDA actually clears an MFU device

The Ministry of Food and Drug Safety, the Korean regulatory body responsible for medical device clearance, runs a tiered classification system that places most MFU lifting platforms in Class III — the highest-risk category for energy-based aesthetic devices — which requires safety and clinical performance data before market entry. The pathway is broadly comparable to the U.S. FDA 510(k) process in scope but moves on a faster average timeline, which is one of the reasons Korean manufacturers can iterate platform generations more quickly than their U.S. counterparts.

What changed in the 2024-2025 window, according to MFDS rule revisions published on the agency's portal, is the addition of clearer documentation requirements for energy-output stability and operator-training claims. That sounds technical, but it has a practical downstream effect: manufacturers who previously cleared a platform on a thinner clinical packet are now expected to update their submissions when they ship cartridge revisions or transducer redesigns. Several Korean platforms went through that update cycle in 2024 — Shurink Universe and Ultraformer III among them — which is why the MFDS clearance dates listed on current marketing materials sometimes look more recent than the platform itself.

A separate point worth noting for international patients: a KFDA clearance is not interchangeable with U.S. FDA clearance. Some Korean platforms hold both, others hold only KFDA. The clinical literature supporting MFU as a category is robust; head-to-head trials between specific cleared platforms remain limited, and that gap shapes how I read manufacturer claims throughout this article.

Sofwave Korea launch and the MFDS file

Sofwave is the Israeli-developed, U.S.-FDA-cleared synchronous ultrasound parallel beam (SUPERB) device that received MFDS clearance for the Korean market through its local distribution partner in 2024, with an expanded indication update logged in early 2025. The clearance covers improvement of facial fine lines and wrinkles and lifting of lax submental and neck tissue — language that mirrors the FDA-cleared indications set, which is typical when an internationally cleared device enters the Korean market through the standard pathway. Sofwave's domestic launch was supported by training rollouts to Gangnam dermatology and aesthetic clinics through 2024, and the platform has been on a meaningful share of pricing sheets since.

For patients, the practical effect of the Korean Sofwave clearance was a price normalization. Before the formal MFDS-cleared distribution, Sofwave sessions in Seoul were either unavailable or quoted at a meaningful premium over the U.S. price. By late 2024, Korean Sofwave pricing had settled into a tier between Ultherapy and the value Korean MFU platforms — usually higher than Shurink Universe and lower than Ultherapy PRIME, though clinic packaging shifts that math. Coverage of the launch in the Korean cosmetic medicine trade press was notable for being consistent across outlets, which is sometimes a useful signal in a market where editorial coverage and sponsored placement can blur.

A conflict-of-interest disclosure I would want any patient to read carefully: Sofwave Medical has historically funded comparative studies between SUPERB and other ultrasound modalities, and several of the most-cited papers list Sofwave Medical-affiliated investigators or carry sponsor disclosure. That does not invalidate the data, but it changes how the data should be weighed against independent or non-sponsored work. I will return to the disclosure point in the comparative-research piece that pairs with this article.

Doublo Gold, Shurink Universe, and the Korean iteration cycle

Two domestic Korean MFU platforms went through MFDS clearance updates in the same 2024 window. Hironic's Doublo Gold filed an indication-expansion update logged on the MFDS device portal in mid-2024, primarily covering refinements to its energy-stability documentation and a cartridge generation update. Classys, the manufacturer behind both Shurink and Ultraformer, filed a Shurink Universe update covering the wider linear cartridge architecture that allows higher line counts in the same session window — the operational change that has shaped how Gangnam practitioners describe the platform to American patients.

The iteration cycle for Korean MFU manufacturers runs roughly two to three years between meaningful platform generations, which is faster than the comparable U.S. cadence. A 2024 review of the Korean aesthetic device market in the Journal of Cosmetic Dermatology noted that Korean manufacturers' iteration cycles have shortened over the past five years, in part because of regulatory accessibility and in part because the domestic clinic market is large enough to absorb new generations quickly. That market dynamic is real and worth knowing — it explains why the Gangnam consultation menu in 2026 looks different from the 2023 menu, and why patients returning after a multi-year gap should expect their clinic to recommend a different platform than the one they had before.

The trade-off is that the published English-language outcome literature on each generation lags the platform's market entry by twelve to twenty-four months. Patients who weight published evidence heavily — and that is a defensible weighting — should ask their provider about the specific generation being recommended and what the clearance and outcome timeline looks like. Studies suggest the broad MFU mechanism is well-supported across Korean and U.S. platforms; the specific generation-versus-generation evidence is where the gap usually lives.

V Max and newer KFDA-cleared entrants

V Max is a category-adjacent ultrasound device cleared by MFDS for facial and body application that has begun appearing on Gangnam pricing sheets since 2024, though its MFU positioning is contested. The device is more accurately described as a high-frequency focused ultrasound platform with a different transducer architecture than the discrete-point MFU that defines Ultherapy and Shurink. Korean clinics often list it adjacent to MFU on the consultation menu, which can confuse patients who assume the listing implies clinical equivalence.

V Max's KFDA clearance was logged in 2023 with subsequent indication updates through 2024, and the device has built a moderate domestic presence in clinics offering bundled lifting-plus-body-contouring packages. For patients, the meaningful question is not whether V Max is a real cleared device — it is. The meaningful question is whether the depth pattern and energy delivery match the indication a patient is bringing to consultation. My honest read, after asking three coordinators about V Max specifically on this trip, is that it is a reasonable option for patients with mild surface laxity and a body-contouring secondary goal, and a less obvious match for patients seeking pronounced SMAS-level facial lifting.

A second newer entrant worth flagging is V-RO, which I covered at greater length in a separate device guide. V-RO's KFDA clearance and market entry strategy fits the broader pattern of Korean manufacturers competing on cartridge cost and operator-training programs rather than on novel mechanism. Patients evaluating these newer entrants should weight the operator's case volume on the specific platform more heavily than the brand label, in my reading. Twelve to twenty-four months of clinic-floor running is roughly the threshold I would want to see before booking a session on a newly cleared platform with a less-experienced operator.

LDM-MED and the adjacent dermal ultrasound category

LDM-MED, the Local Dynamic Micromassage device produced by Wellcomet, is a German-developed dermal ultrasound platform with an MFDS clearance pathway that runs separate from the MFU lifting category but appears on Korean clinic menus often enough to deserve a paragraph. The device delivers dual-frequency ultrasound at lower energy levels than MFU lifting platforms and is positioned for skin-quality, post-procedure recovery, and inflammation-focused indications rather than structural lifting. Recent MFDS documentation updates in 2024-2025 covered iteration of the LDM-MED handpiece and treatment-protocol claims, which has expanded the device's listing on Gangnam clinic protocols.

For patients, LDM-MED is a different category. It is not a substitute for MFU lifting, and most experienced operators are clear about the distinction in consultation. Where LDM-MED has begun showing up more frequently is in post-MFU recovery protocols, where the dermal ultrasound is used to support tissue response in the days following an MFU session. Patients report this combination is comfortable and well-tolerated; the published evidence on whether the combination meaningfully extends the MFU result curve is limited, and I would describe the combination as well-supported on safety grounds and inconclusive on outcome enhancement. May help is the right framing.

A broader regulatory point: the MFDS device portal categorizes ultrasound aesthetic devices into several risk classes, and the Class II versus Class III distinction shapes clearance timelines and documentation requirements. LDM-MED and similar dermal ultrasound platforms typically clear at a lower risk class than MFU lifting devices, which is part of why their iteration cycle moves faster. That regulatory distinction is one a patient should not need to know — but practitioners' fluency with which platform is cleared for which indication is a reasonable filter for which clinic to book with.

What the 2024-2026 clearance picture means for patients

The headline from two years of MFDS clearance activity is that the Korean MFU and adjacent-ultrasound device menu has expanded materially, and the older default — Ultherapy versus Shurink with a polite mention of Doublo — is no longer descriptive. Patients walking into a Gangnam consultation in 2026 should expect to see at least four MFU options on the consultation sheet, plus Sofwave as a category-different alternative, plus dermal ultrasound platforms positioned for adjunct or recovery use. The right device for a specific patient depends on indication match, operator platform familiarity, and budget — none of which a clearance date captures.

A reporter-flavored caveat I want to put on the record: the volume of platform options is a feature for clinics that have invested in operator training across multiple devices, and a complication for clinics that have not. The most useful question a patient can ask in consultation is how many cases the practitioner has personally run on the recommended platform in the past twelve months. The answer varies more across clinics than the brochure suggests, and it correlates more strongly with outcome consistency than the device label does. Studies suggest the broad MFU mechanism is well-supported across cleared platforms; the operator's hand on the platform she runs the most is what produces the result a patient actually walks out with.

For American patients tracking Korean MFU device updates from outside the country, the FDA database and the MFDS device portal are both publicly searchable, and English-language coverage in the Korean cosmetic medicine trade press has improved since 2023. Cross-referencing the manufacturer's own clearance claims against the regulator's primary documentation is a habit worth keeping. Marketing copy ages faster than clearance records, and the gap between what a brochure claims and what a regulator has actually cleared is the kind of detail that occasionally matters.

Frequently asked questions

Is KFDA clearance the same as U.S. FDA clearance?

No. The Korean Ministry of Food and Drug Safety (MFDS, sometimes called KFDA) and the U.S. FDA are separate regulatory bodies with overlapping but distinct documentation standards. Some MFU devices hold both clearances (Ultherapy, Sofwave); some hold only one. A KFDA-cleared device legally distributed in Korea is not automatically FDA-cleared in the U.S., and patients planning to discuss the procedure with a U.S. provider after returning should know which clearances the platform carries.

When did Sofwave officially launch in Korea?

Sofwave received MFDS clearance through its local distribution partner in 2024, with an indication update logged in early 2025. By late 2024, the platform was on a meaningful share of Gangnam clinic pricing sheets at a tier between Ultherapy and the value Korean MFU platforms. The clearance covers improvement of facial fine lines and lifting of lax submental and neck tissue, mirroring its U.S. FDA-cleared indications.

How often do Korean MFU manufacturers iterate their platforms?

Roughly every two to three years between meaningful platform generations, which is faster than the comparable U.S. cadence. The faster cycle is partly a function of the MFDS clearance pathway timeline and partly a function of the size of the domestic Korean clinic market, which absorbs new generations quickly. Patients returning to Gangnam after a multi-year gap should expect their clinic to recommend a different generation than the one they had before.

Should I prefer a recently cleared platform or an established one?

For most patients, an established platform with at least eighteen to twenty-four months of clinic-floor running and an operator who has logged meaningful case volume on it is the more predictable choice. Newly cleared platforms can be excellent in the right hands but carry less published outcome data and less operator-track-record certainty. Studies suggest the broad MFU mechanism is well-supported across cleared platforms; the specific generation-versus-generation evidence often lags clearance by twelve to twenty-four months.

Where can I verify a Korean MFU device's KFDA clearance directly?

The MFDS medical device portal is publicly searchable in Korean and offers an English-language interface for several device categories. The U.S. FDA 510(k) database covers devices with U.S. clearance. Cross-referencing manufacturer claims against the regulator's primary documentation is a habit worth keeping, particularly when marketing copy makes generation-specific or indication-specific claims that may not appear in the cleared documentation.

Is V Max actually an MFU device?

Its category positioning is contested. V Max is more accurately described as a high-frequency focused ultrasound platform with a different transducer architecture than the discrete-point MFU that defines Ultherapy and Shurink. Korean clinics sometimes list it adjacent to MFU on consultation menus, which can confuse patients who assume the listing implies clinical equivalence. Ask the practitioner directly which platform category she places V Max in and why, and weight her answer against the indication you are bringing to consultation.